Literature DB >> 15607385

A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics.

Anna Birna Almarsdóttir1, Ingunn Björnsdóttir, Janine Morgall Traulsen.   

Abstract

This study explores the lay view of pharmaceutical research and development--specifically pharmacogenomics. Forty-two persons participated in eight focus groups in Iceland. Participants were asked to comment on a future scenario consisting of predictions made by researchers concerning the consequences of the Human Genome Project over the next 40 years, and asked to give advice to politicians and the pharmaceutical industry. A dominating theme in the focus groups was the expectation that drugs developed based on pharmacogenomics will be more expensive than conventional mass produced drugs and concerns were voiced that this new technology would lead to inequalities locally and globally.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach; Genetics and Reproduction

Mesh:

Year:  2005        PMID: 15607385     DOI: 10.1016/j.healthpol.2004.08.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  17 in total

1.  The potential impact of pharmacogenetic testing on medication adherence.

Authors:  S B Haga; N M A LaPointe
Journal:  Pharmacogenomics J       Date:  2013-09-03       Impact factor: 3.550

2.  Rational use of medicines--an important issue in pharmaceutical policy.

Authors:  Anna Birna Almarsdóttir; Janine M Traulsen
Journal:  Pharm World Sci       Date:  2005-04

3.  Patient experiences with pharmacogenetic testing in a primary care setting.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb; Nancy Allen Lapointe; Alex Cho; Geoffrey S Ginsburg
Journal:  Pharmacogenomics       Date:  2016-09-20       Impact factor: 2.533

4.  Public perspectives about pharmacogenetic testing and managing ancillary findings.

Authors:  Susanne B Haga; Genevieve Tindall; Julianne M O'Daniel
Journal:  Genet Test Mol Biomarkers       Date:  2011-11-02

5.  Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.

Authors:  Rachel Mills; Susanne B Haga
Journal:  Pharmacogenomics       Date:  2013-06       Impact factor: 2.533

Review 6.  Ethical considerations for pharmacogenomic testing in pediatric clinical care and research.

Authors:  Cassandra Moran; Courtney D Thornburg; Raymond C Barfield
Journal:  Pharmacogenomics       Date:  2011-06       Impact factor: 2.533

7.  Pharmaceutical policy and the lay public.

Authors:  Janine M Traulsen; Anna Birna Almarsdóttir
Journal:  Pharm World Sci       Date:  2005-08

8.  International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.

Authors:  Naveen L Pereira; Derek So; Jang-Ho Bae; Ivan Chavez; Myung Ho Jeong; Sang Wook Kim; Mina Madan; John Graham; Fearghas O'Cochlain; Nicole Pauley; Ryan J Lennon; Kent Bailey; Ahmed Hasan; Linnea M Baudhuin; Malcolm R Bell; Amir Lerman; Shaun Goodman; Verghese Mathew; Michael Farkouh; Charanjit S Rihal
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

9.  Views on personalized medicine: do the attitudes of African American and white prescription drug consumers differ?

Authors:  M De Marco; S Cykert; N Coad; K Doost; J Schaal; B White; D Young; M R Isler; G Corbie-Smith
Journal:  Public Health Genomics       Date:  2009-09-23       Impact factor: 2.000

10.  Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.

Authors:  J M Pulley; J C Denny; J F Peterson; G R Bernard; C L Vnencak-Jones; A H Ramirez; J T Delaney; E Bowton; K Brothers; K Johnson; D C Crawford; J Schildcrout; D R Masys; H H Dilks; R A Wilke; E W Clayton; E Shultz; M Laposata; J McPherson; J N Jirjis; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.